Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Interest & Investment Income (2022 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Interest & Investment Income for 3 consecutive years, with $80483.0 as the latest value for Q4 2024.

  • Quarterly Interest & Investment Income fell 53.43% to $80483.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $423184.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $327193.0 for FY2025, 22.68% down from the prior year.
  • Interest & Investment Income hit $80483.0 in Q4 2024 for Pasithea Therapeutics, up from $75076.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $172825.0 in Q4 2023 to a low of -$335317.0 in Q3 2022.
  • Historically, Interest & Investment Income has averaged $56061.7 across 3 years, with a median of $114407.0 in 2024.
  • Biggest five-year swings in Interest & Investment Income: surged 139.29% in 2023 and later crashed 53.43% in 2024.
  • Year by year, Interest & Investment Income stood at -$335317.0 in 2022, then soared by 151.54% to $172825.0 in 2023, then tumbled by 53.43% to $80483.0 in 2024.
  • Business Quant data shows Interest & Investment Income for KTTA at $80483.0 in Q4 2024, $75076.0 in Q3 2024, and $114407.0 in Q2 2024.